Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manlio Ferrarini

Showing results (81-90 of 123) with videos related to

Pageof 13
Sort By:
British Journal of Haematology|May 15, 2009
Definition of progression risk based on combinations of cellular and molecular markers in patients with Binet stage A chronic lymphocytic leukaemiaFortunato Morabito, Giovanna Cutrona, Massimo Gentile, et al.
International Journal of Molecular Sciences|February 13, 2026
Intraclonal Enrichment of IL-23 Receptor Complex Expression in the Proliferative Fraction of Chronic Lymphocytic LeukemiaMartina Cardillo, Fabiana Ferrero, Nadia Bertola, et al.
Haematologica|February 20, 2025
Chronic lymphocytic leukemia often arises by a multiclonal selection processDavide Bagnara, Andrea N Mazzarello, Niccolò Cardente, et al.
American Journal of Hematology|April 9, 2014
Prospective validation of a risk score based on biological markers for predicting progression free survival in Binet stage A chronic lymphocytic leukemia patients: results of the multicenter O-CLL1-GISL studyMassimo Gentile, Giovanna Cutrona, Laura Mosca, et al.
Scientific Reports|October 29, 2020
Time to first treatment and P53 dysfunction in chronic lymphocytic leukaemia: results of the O-CLL1 study in early stage patientsPaola Monti, Marta Lionetti, Giuseppa De Luca, et al.
American Journal of Hematology|July 29, 2016
The chronic lymphocytic leukemia international prognostic index predicts time to first treatment in early CLL: Independent validation in a prospective cohort of early stage patientsStefano Molica, Tait D Shanafelt, Diana Giannarelli, et al.
Hematological Oncology|February 26, 2020
Frequency and clinical relevance of coding and noncoding NOTCH1 mutations in early stage Binet A chronic lymphocytic leukemia patientsMarta Lionetti, Marzia Barbieri, Vanessa Favasuli, et al.
Hematological Oncology|August 12, 2022
The spectrum of subclonal TP53 mutations in chronic lymphocytic leukemia: A next generation sequencing retrospective studyGiuseppa De Luca, Giannamaria Cerruti, Sonia Lastraioli, et al.
Plos One|September 8, 2011
Relevance of stereotyped B-cell receptors in the context of the molecular, cytogenetic and clinical features of chronic lymphocytic leukemiaFrancesco Maura, Giovanna Cutrona, Sonia Fabris, et al.
Leukemia Research|June 4, 2015
Surrogate molecular markers for IGHV mutational status in chronic lymphocytic leukemia for predicting time to first treatmentFortunato Morabito, Giovanna Cutrona, Laura Mosca, et al.
Pageof 13

Showing results (81-90 of 123) with videos related to

Sort By:
Pageof 13
British Journal of Haematology|May 15, 2009
Definition of progression risk based on combinations of cellular and molecular markers in patients with Binet stage A chronic lymphocytic leukaemiaFortunato Morabito, Giovanna Cutrona, Massimo Gentile, et al.
International Journal of Molecular Sciences|February 13, 2026
Intraclonal Enrichment of IL-23 Receptor Complex Expression in the Proliferative Fraction of Chronic Lymphocytic LeukemiaMartina Cardillo, Fabiana Ferrero, Nadia Bertola, et al.
Haematologica|February 20, 2025
Chronic lymphocytic leukemia often arises by a multiclonal selection processDavide Bagnara, Andrea N Mazzarello, Niccolò Cardente, et al.
American Journal of Hematology|April 9, 2014
Prospective validation of a risk score based on biological markers for predicting progression free survival in Binet stage A chronic lymphocytic leukemia patients: results of the multicenter O-CLL1-GISL studyMassimo Gentile, Giovanna Cutrona, Laura Mosca, et al.
Scientific Reports|October 29, 2020
Time to first treatment and P53 dysfunction in chronic lymphocytic leukaemia: results of the O-CLL1 study in early stage patientsPaola Monti, Marta Lionetti, Giuseppa De Luca, et al.
American Journal of Hematology|July 29, 2016
The chronic lymphocytic leukemia international prognostic index predicts time to first treatment in early CLL: Independent validation in a prospective cohort of early stage patientsStefano Molica, Tait D Shanafelt, Diana Giannarelli, et al.
Hematological Oncology|February 26, 2020
Frequency and clinical relevance of coding and noncoding NOTCH1 mutations in early stage Binet A chronic lymphocytic leukemia patientsMarta Lionetti, Marzia Barbieri, Vanessa Favasuli, et al.
Hematological Oncology|August 12, 2022
The spectrum of subclonal TP53 mutations in chronic lymphocytic leukemia: A next generation sequencing retrospective studyGiuseppa De Luca, Giannamaria Cerruti, Sonia Lastraioli, et al.
Plos One|September 8, 2011
Relevance of stereotyped B-cell receptors in the context of the molecular, cytogenetic and clinical features of chronic lymphocytic leukemiaFrancesco Maura, Giovanna Cutrona, Sonia Fabris, et al.
Leukemia Research|June 4, 2015
Surrogate molecular markers for IGHV mutational status in chronic lymphocytic leukemia for predicting time to first treatmentFortunato Morabito, Giovanna Cutrona, Laura Mosca, et al.
Pageof 13